Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.62 USD | +3.55% | -2.69% | +13.84% |
Financials (USD)
Sales 2024 * | 14.91M | Sales 2025 * | 82.05M | Capitalization | 1.45B |
---|---|---|---|---|---|
Net income 2024 * | -247M | Net income 2025 * | -202M | EV / Sales 2024 * | 84.2 x |
Net cash position 2024 * | 196M | Net cash position 2025 * | 212M | EV / Sales 2025 * | 15.1 x |
P/E ratio 2024 * |
-5.91
x | P/E ratio 2025 * |
-7.77
x | Employees | 174 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.31% |
Latest transcript on Day One Biopharmaceuticals, Inc.
1 day | +3.55% | ||
1 week | -2.69% | ||
Current month | -2.81% | ||
1 month | +20.70% | ||
3 months | +12.68% | ||
6 months | +36.57% | ||
Current year | +13.84% |
Managers | Title | Age | Since |
---|---|---|---|
Samuel Blackman
FOU | Founder | 55 | 18-10-31 |
Jeremy Bender
CEO | Chief Executive Officer | 52 | 20-08-31 |
Charles York
DFI | Director of Finance/CFO | 47 | 21-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
J. Garland
BRD | Director/Board Member | 55 | 21-08-16 |
Natalie Holles
BRD | Director/Board Member | 51 | 21-01-31 |
John Josey
BRD | Director/Board Member | 63 | 20-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.04% | 1,487 M€ | +7.21% | - | |
0.01% | 9 M€ | +9.94% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 16.62 | +3.55% | 331,987 |
24-05-13 | 16.05 | +0.31% | 467,496 |
24-05-10 | 16 | -2.32% | 734,965 |
24-05-09 | 16.38 | -0.18% | 677,734 |
24-05-08 | 16.41 | -3.92% | 603,191 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.84% | 1.45B | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+43.45% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- DAWN Stock